Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | LPL | P06858 | 6/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22448147 | 0.79 | LIPG (0.54) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL4154520 | 0.79 | QDPR (0.40) | — | |
| SCHEMBL30919843 | 0.79 | P2RX7 (0.47) | P2RX7PPARAHTR1ALPLLIPG | |
| SCHEMBL31334233 | 0.75 | LIPG (0.43) | P2RX7HTR1ALPLLIPGBACE1 | |
| SCHEMBL12845155 | 0.75 | LIPG (0.53) | P2RX7LPLLIPG | |
| SCHEMBL12373176 | 0.75 | LPL (0.44) | P2RX7MAPK1LPLLIPGFFAR1 | |
| SCHEMBL4161348 | 0.74 | QDPR (0.46) | — | |
| SCHEMBL22448166 | 0.74 | LIPG (0.51) | P2RX7LPLLIPGBACE1 | |
| SCHEMBL3796275 | 0.72 | LIPG (0.62) | PDGFRBLPLLIPG | |
| SCHEMBL25160238 | 0.71 | P2RX7 (0.39) | P2RX7LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | P2RX7 821/4885PDGFRB 221/4885PDGFRA 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.